Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Results of Operations and Financial Condition

Item2.02

Five Prime Therapeutics, Inc. (FivePrime) is in the process of
finalizing its financial results for the fiscal year ended
December31, 2016. Set forth below is a preliminary estimate of
FivePrimes cash and cash equivalents and outstanding shares for
the fiscal year ended December31, 2016, a forecast of FivePrimes
estimated net cash used in operations for fiscal year 2017 and a
forecast of FivePrimes estimated cash, cash equivalent and
marketable securities as of December31, 2017, based on
information currently available as of the date of this Current
Report.

FivePrime estimates that its cash, cash equivalents and
marketable securities as of December31, 2016 was approximately
$421.7 million. FivePrime estimates that it had 28.6million
shares of common stock outstanding as of December31, 2016.
FivePrimes actual consolidated cash, cash equivalents and
marketable securities balance and shares of common stock
outstanding as of December31, 2016 may differ from these
estimates due to the completion of FivePrimes year-end closing
and auditing procedures.

FivePrime expects net cash used in operations for fiscal year
2017 will be less than $120 million. FivePrime expects that its
cash, cash equivalents and marketable securities as of December
31, 2017 will be approximately $300 million.

The information provided in this Item 7.01 is furnished to
Regulation FD and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing.

Cautionary Note on Forward-looking Statements

This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as may, will, expect,
plan, anticipate, estimate, intend and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on FivePrimes expectations and assumptions as of the date
of this Current Report. Each of these forward-looking statements
involves risks and uncertainties. Actual results may differ
materially from these forward-looking statements. Forward-looking
statements contained in this Current Report include statements
about FivePrimes (i) estimated net cash used in operating
activities for fiscal year 2017 and (ii) estimated cash, cash
equivalents and marketable securities as of December31, 2017.
Other factors that may cause FivePrimes actual results to differ
from those expressed or implied in the forward-looking statements
in this Current Report are discussed in FivePrimes filings with
the U.S. Securities and Exchange Commission, including the Risk
Factors sections contained therein. Except as required by law,
FivePrime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in
expectations, even as new information becomes available.

2

About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)

Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Recent Trading Information

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) closed its last trading session down -0.40 at 51.33 with 433,980 shares trading hands.